Home › Acute Myeloid Leukemia › Illinois
Acute Myeloid Leukemia clinical trials in Illinois
31 studies for Acute Myeloid Leukemia are looking for participants at sites in Illinois.
Cities in Illinois
- Chicago26 studies
- Evanston11 studies
- Cicero11 studies
- Springfield8 studies
- Decatur7 studies
- Peoria6 studies
- Joliet5 studies
- Waukegan5 studies
- Naperville5 studies
- Galesburg4 studies
- North Peoria4 studies
- Bloomington4 studies
- Aurora4 studies
- Danville3 studies
- Charleston3 studies
- Champaign3 studies
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- and 15 more
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Oct 2, 2026 · NCT07437950Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- and 54 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Centralia Oncology Clinic, Centralia
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 13 more
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 28, 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Chicago Medicine, Chicago
- Illinois Cancer Specialists, Niles
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- OSF Saint Joseph Medical Center, Bloomington
- and 54 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Lurie Children's Hospital-Chicago, Chicago
RecruitingPhase 1
Up to age 21 · All sexes · Updated Sep 23, 2026 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 26 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 14 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- and 29 more
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 22, 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 5 more
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- The University of Chicago Medical Center, Chicago
RecruitingPhase 1/2
30 Days · All sexes · Updated Sep 16, 2026 · NCT04065399A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- University of Chicago, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06969430Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Lurie Children's Hospital-Chicago, Chicago
RecruitingPhase 3
Ages 1 to 25 · All sexes · Updated Sep 4, 2026 · NCT07022678Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Chicago, Zion
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Chigago IL-UHCHICAGO, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT07223814A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 25, 2026 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 6 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
- Comer Children's Hospital, Chicago
RecruitingPhase 3
29 Days – 21 Years · All sexes · Updated Aug 24, 2026 · NCT05183035Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- Loyola University Medical Center, Maywood
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Decatur
RecruitingPhase 1/2
Ages 16 and older · All sexes · Updated Jul 20, 2026 · NCT07155226A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- and 3 more
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
- University of Illinois Cancer Center, Chicago
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jun 26, 2026 · NCT06802315Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
RecruitingPhase 1
Ages 13 and older · All sexes · Updated May 5, 2026 · NCT04771572A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Northwestern University, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT05732103A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Northwestern Medicine, Chicago
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Mar 16, 2026 · NCT06994676A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- Loyola University Medical Center, Maywood
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Northshore University Health System, Evanston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 23, 2026 · NCT05974150A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT06501196Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Northwestern University, Evanston
RecruitingHealthy volunteers welcome
Ages 18 to 120 · All sexes · Updated Jul 25, 2025 · NCT05237258From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.